The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions regarding the workup of patients with prostate cancer, risk stratification and management of localized disease, post-treatment monitoring, and treatment of recurrence and advanced disease. The Guidelines sections included in this article focus on the management of metastatic castration-sensitive disease, nonmetastatic castration-resistant prostate cancer (CRPC), and metastatic CRPC (mCRPC). Androgen deprivation therapy (ADT) with treatment intensification is strongly recommended for patients with metastatic castration-sensitive prostate cancer. For patients with nonmetastatic CRPC, ADT is continued with or without the addition of certain secondary hormone therapies depending on prostate-specific antigen doubling time. In the mCRPC setting, ADT is continued with the sequential addition of certain secondary hormone therapies, chemotherapies, immunotherapies, radiopharmaceuticals, and/or targeted therapies. The NCCN Prostate Cancer Panel emphasizes a shared decision-making approach in all disease settings based on patient preferences, prior treatment exposures, the presence or absence of visceral disease, symptoms, and potential side effects.
Journal of the National Comprehensive Cancer Network : JNCCN. 2023 Oct [Epub]
Edward M Schaeffer, Sandy Srinivas, Nabil Adra, Yi An, Daniel Barocas, Rhonda Bitting, Alan Bryce, Brian Chapin, Heather H Cheng, Anthony Victor D'Amico, Neil Desai, Tanya Dorff, James A Eastham, Thomas A Farrington, Xin Gao, Shilpa Gupta, Thomas Guzzo, Joseph E Ippolito, Michael R Kuettel, Joshua M Lang, Tamara Lotan, Rana R McKay, Todd Morgan, George Netto, Julio M Pow-Sang, Robert Reiter, Mack Roach, Tyler Robin, Stan Rosenfeld, Ahmad Shabsigh, Daniel Spratt, Benjamin A Teply, Jonathan Tward, Richard Valicenti, Jessica Karen Wong, Dorothy A Shead, Jenna Snedeker, Deborah A Freedman-Cass
Robert H. Lurie Comprehensive Cancer Center of Northwestern University., Stanford Cancer Institute., Indiana University Melvin and Bren Simon Comprehensive Cancer Center., Yale Cancer Center/Smilow Cancer Hospital., Vanderbilt-Ingram Cancer Center., Duke Cancer Institute., Mayo Clinic Comprehensive Cancer Center., The University of Texas MD Anderson Cancer Center., Fred Hutchinson Cancer Center., Dana-Farber/Brigham and Women's Cancer Center | Mass General Cancer Center., UT Southwestern Simmons Comprehensive Cancer Center., City of Hope National Cancer Center., Memorial Sloan Kettering Cancer Center., Prostate Health Education Network (PHEN)., Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute., Abramson Cancer Center at The University of Pennsylvania., Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine., Roswell Park Comprehensive Cancer Center., University of Wisconsin Carbone Cancer Center., The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins., UC San Diego Moores Cancer Center., University of Michigan Rogel Cancer Center., O'Neal Comprehensive Cancer Center at UAB., Moffitt Cancer Center., UCLA Jonsson Comprehensive Cancer Center., UCSF Helen Diller Family Comprehensive Cancer Center., University of Colorado Cancer Center., University of California San Francisco, Patient Services Committee Chair., The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute., Fred & Pamela Buffett Cancer Center., Huntsman Cancer Institute at the University of Utah., UC Davis Comprehensive Cancer Center., Fox Chase Cancer Center., National Comprehensive Cancer Network.